Preview

Научно-практическая ревматология

Расширенный поиск

Современная стратегия лечения болезни депонирования кристаллов пирофосфата кальция

https://doi.org/10.14412/1995-4484-2018-746-752

Полный текст:

Аннотация

Рассмотрены современные средства для лечения болезни депонирования кристаллов пирофосфата кальция. Обсуждены преимущества и недостатки наиболее широко применяемых медикаментов: нестероидных противовоспалительных препаратов, колхицина, глюкокортикоидов, традиционных иммунодепрессантов, перспективы применения генно-инженерных биологических препаратов.

Об авторах

С. А. Владимиров
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой».
Россия

научный сотрудник лаборатории микрокристаллических артритов.

Москва, Россия 115522 Москва, Каширское шоссе, 34А.



М. С. Елисеев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой».
Россия

заведующий лабораторией микрокристаллических артритов.

Москва, Россия 115522 Москва, Каширское шоссе, 34А.



Список литературы

1. Hollander JL, Jessar RA, McCarty DJ. Synovianalysis: an aid in arthritis diagnosis. Bull Rheum Dis. 1961;(12):263-4.

2. Кудаева ФМ, Владимиров СА, Елисеев МС и др. Особенности клинических проявлений болезни депонирования кристаллов пирофоасфата кальция. Научно-практическая ревматология. 2014;52(4):405-9 [Kudaeva FM, Vladimirov SA, Eliseev MS, et al. The clinical manifestations of calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):405-9 (In Russ.)]. doi: 10.14412/1995-4484-2014-405-409

3. Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford). 2009;48:711-5. doi: 10.1093/rheumatology/kep081

4. Doherty M. Calcium pyrophosphate dihydrate crystal-associated arthropathy. In: Hochberg M, ed. Rheumatology. Edinburgh: Mosby; 2003. P. 1937-50

5. Neame RL, Carr AJ, Muir K, Doherty M. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. 2003;62:513-8. doi: 10.1136/ard.62.6.513

6. Felson DT, Anderson JJ, Naimark A, et al. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol. 1989;16(9):1241-5.

7. Sanmarti R, Panella D, Brancos MA, et al. Prevalence of articular chondrocalcinosis in elderly subjects in a rural area of Catalonia. Ann Rheum Dis. 1993;52:418-22. doi: 10.1136/ard.52.6.418

8. Saadeh C. Calcium Pyrophosphate Deposition Disease. Medscape, 09.2009. Доступно по ссылке:

9. https://emedicine.medscape.com/article/330936-overview

10. Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005;23:819-28.

11. Елисеев МС, Владимиров СА. Распространенность и клинические особенности подагры и болезни депонирования пирофосфата кальция у пациентов с острым артритом. Научно-практическая ревматология. 2015;53(4):375-8 [Eliseev MS, Vladimirov SA. The prevalence and clinical features of gout and calcium pyrophosphate deposition disease in patients with acute arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;53(4):375-8 (In Russ.)]. doi: 10.14412/1995-4484-2015-375-378

12. Zhang W, Doherty M, Bardin T, Barskova V, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70:563-70. doi: 10.1136/ard.2010.139105

13. Rosenthal AK, Ryan LM. Crystal arthritis: calcium pyrophosphate deposition-nothing ‘pseudo’ about it! Nat Rev Rheumatol. 2011;7(5):257-8. doi: 10.1038/nrrheum.2011.50

14. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;6:29-42. doi: 10.1136/annrheumdis-2016-209707

15. Sivera F, Andres M, Pascual E. Current advances in therapies for calcium pyrophosphate crystal arthritis. Curr Opin Rheumatol. 2016;28(2):140-4. doi: 10.1097/BOR.0000000000000252

16. Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheum Dis. 1983;42:106-7. doi: 10.1136/ard.42.Suppl_1.106

17. Ritter K, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994;21(4):696-9.

18. Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Joint Bone Spine. 2014;81(1):98-100. doi: 10.1016/j.jbspin.2013.05.006

19. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendation for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-24. doi: 10.1136/ard.2006.055269

20. Terkeltaub RA, Furst DE, Bennett K, et al. High-vs low-dosing of oral colchicine for early acute gout flare: Twenty-four hour outcome results of the first randomized, placebocontrolled, dose comparison colchicine trial. Arthritis Rheum. 2010 Apr;62(4):1060-8. doi: 10.1002/art.27327

21. Announ N, Guerne P-A. Treating diffilt crystal pyrophosphate dihydrate deposition disease. Curr Rheumatol Rep. 2008;10(3):228-34. doi: 10.1007/s11926-008-0037-2

22. Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986;13(4):804-5.

23. Das SK, Mishra K, Ramakrishnah S, et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthr Cartilage. 2002;10:247-52. doi: 10.1053/joca.2002.0516

24. Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen or naproxen: a secondary analysis of the PRECISION trial. Am J Med. 2017;130(12):1415-22 doi: 10.1016/j.amjmed.2017.06.028

25. Елисеев МС, Желябина ОВ. Сочетание подагры и болезни депонирования пирофосфатов кальция: трудности диагностики и лечения. РМЖ. Медицинское обозрение. 2017;(1):44-7 [Eliseev MS, Zhelyabina OV. The combination of gout and the disease of calcium pyrophosphate deposition: the difficulties of diagnosis and treatment. RMZh. Meditsinskoe Obozrenie. 2017;(1):44-7 (In Russ.)].

26. Елисеев МС, Владимиров СА. Применение мелоксикама (Амелотекс®) у больных пирофосфатной артропатией. Cовременная ревматология. 2011;5(3):34-6 [Eliseev MS, Vladimirov SA. Use of meloxicam (Amelotex®) in patients with pyrophosphate arthropathy. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2011;5(3):34-7 (In Russ.)]. doi: 10.14412/1996-7012-2011-682

27. Andres M, Sivera F, Pascual E. Therapy for CPPD: Options and Evidence. Curr Rheumatol Rep. 2018 Apr 19;20(6):31. doi: 10.1007/s11926-018-0739-z

28. Rosenthal AK. Update in calcium deposition diseases. Curr Opin Rheumatol. 2007;19(2):158-62. doi: 10.1097/BOR.0b013e3280145289

29. Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed. 1996;63(4):248-54.

30. Roane DW, Harris MD, Carpenter MT, et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol. 1997;24(6):1168-70.

31. Potvin F, Petitclerc E, Marceau F. Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. J Immun. 1997;158:1872-9.

32. Rothschild B, Yakubov LE. Prospective 6-month, doubleblind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997 May;23(5):327-31.

33. Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007;56:688-92. doi: 10.1002/art.22389

34. Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012;18:234-6. doi: 10.1097/RHU.0b013e3182611471

35. Doan TH, Chevalier X, Leparc JM, et al. Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum. 2008;58:2210-1. doi: 10.1002/art.23552

36. Finckh A, Mc Carthy GM, Madigan A, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014 Oct 15;16:458. doi: 10.1186/s13075-014-0458-4

37. Pascual E, Andres M, Sivera F. Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease? Arthritis Res Ther. 2015 Apr 1;17:89. doi: 10.1186/s13075-015-0598-1

38. Theiler G, Quehenberger F, Rainer F, et al. The detection of calcium pyrophosphate crystals in the synovial fluid of patients with rheumatoid arthritis using the cytospin technique: prevalence and clinical correlation. Rheumatol Int. 2014;34:137-9. doi: 10.1007/s00296-012-2608-9

39. Oliviero F, Scanu A, Galozzi P, et al. Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine. 2013;80:287-90. doi: 10.1016/j.jbspin.2012.08.006

40. Елисеев МС, Владимиров СА, Насонов ЕЛ. Применение метотрексата у больных с болезнью депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(2):196-201 [Eliseev MS, Vladimirov SA, Nasonov EL. Use of methotrexate in patients with calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(2):196-201 (In Russ.)]. doi: 10.14412/1995-4484-2018-196-201

41. Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77 [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77

42. Елисеев МС, Барскова ВГ, Насонов ЕЛ. Канакинумаб (ингибитор интелейкина 1) – прорыв в возможностях противовоспалительной терапии при подагре. Научно-практическая ревматология. 2013;51(4):428-31 [Eliseev MS, Barskova VG, Nasonov EL. Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(4):428-31 (In Russ.)]. doi: 10.14412/1995-4484-2013-1255

43. Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374:2575-84. doi: 10.1056/NEJMra1511117

44. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 2008;58:631-3. doi: 10.1002/art.23119

45. Announ N, Palmer G, Guerne PA, Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine. 2009;76:424-6. doi: 10.1016/j.jbspin.2009.01.001

46. Couderc M, Mathieu S, Glace B, Soubrier M. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine. 2012;79:330-1. doi: 10.1016/j.jbspin.2011.12.017

47. Molto A, Ea HK, Richette P, et al. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine. 2012;79:621-3. doi: 10.1016/j.jbspin.2012.01.010

48. Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G. Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J Clin Rheumatol. 2012;18:310-1. doi: 10.1097/RHU.0b013e31826149a2

49. Ottaviani S, Brunier L, Sibilia J, et al. Efficacy of anakinra in calcium pyrophosphate crystal induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine. 2013;80:178-82. doi: 10.1016/j.jbspin.2012.07.018

50. Aouba A, Deshayes S, Frenzel L, et al. Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature. Mediat Inflamm. 2015;2015:792173. doi: 10.1155/2015/792173

51. Bruges-Armas J, Bettencourt BF, Couto AR, et al. Effectiveness and safety of infliximab in two cases of severe chondrocalcinosis: nine years of follow-up. Case Rep Rheumatol. 2014;2014:536856. doi: 10.1155/2014/536856

52. Quilis N, Andres M, Vela P, Pascual E. Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: two cases report. Joint Bone Spine. 2018 May;85(3):377-8. doi: 10.1016/j.jbspin.2017.04.008

53. Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum. 1989;32:1443-52. doi: 10.1002/anr.1780321114

54. Danino O, Svetitsky S, Kenigsberg S, et al. Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug. Rheumatology (Oxford). 2018 Aug 1;57(8):1472-80. doi: 10.1093/rheumatology/key092


Для цитирования:


Владимиров С.А., Елисеев М.С. Современная стратегия лечения болезни депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(6):746-752. https://doi.org/10.14412/1995-4484-2018-746-752

For citation:


Vladimirov S.A., Eliseev M.S. Current strategy in the treatment of calcium pyrophosphate crystal deposition disease. Rheumatology Science and Practice. 2018;56(6):746-752. (In Russ.) https://doi.org/10.14412/1995-4484-2018-746-752

Просмотров: 277


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)